Idelalisib
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Idelalisib (ncit:C78825)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| Sensitivity (+) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Ofatumumab | |
| Sensitivity (+) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Ofatumumab | |
| Sensitivity (+) | 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Ofatumumab |